Brief SEE FAR CBT Intervention Compared With Treatment as Usual for Adults With PTSD

A Clinical Study Evaluating the Effects of a Brief SEE FAR CBT Intervention Compared With Dynamic Psychotherapy Treatment as Usual on Psychological Outcomes in Adults With Posttraumatic Stress Disorder

This clinical intervention study evaluates a newly developed Brief SEE FAR CBT protocol for adults aged 18 years and older with posttraumatic stress disorder (PTSD), compared with dynamic psychotherapy treatment as usual. Participants in the Brief SEE FAR CBT group will receive 6 focused sessions emphasizing intrusive PTSD symptoms and will then continue to complete the full 12-session SEE FAR CBT protocol. Participants in the control group will receive dynamic psychotherapy as treatment as usual. Psychological outcomes will be assessed using self-report questionnaires at four time points: baseline, after 6 sessions, after 12 sessions, and at a 3-month follow-up. The study aims to examine changes in PTSD symptoms, anxiety, depression, perceived stress, resilience, somatic symptoms, sleep quality, and related psychological outcomes over the course of treatment and follow-up.

Study Overview

• Status: Recruiting
• Conditions: Post Traumatic Stress Disorder
• Intervention / Treatment: Behavioral: Brief SEE FAR CBT Intervention; Behavioral: Dynamic Psychotherapy Treatment as Usual

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Meital Mashash, PhD; Phone Number: 972-50-2888052; Email: meitalm@icspc.org
• Study Contact Backup: Name: Sivan Raz, PhD; Phone Number: 972-54-6634301; Email: sivanra@telhai.ac.il

Study Locations

• Israel
  • Sha'ar Hanegev, Israel
    • Recruiting
    • The Center for Psychological Services Sha'ar Hanegev
    • Contact: Tal Eilon; Phone Number: 972-77-9802751; Email: tale@mpsy.org.il

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

Participants must meet all of the following criteria:

• Age 18 years or older
• PTSD symptoms, defined as a PCL-5 score of 30-60
• Hebrew-speaking
• Able to provide informed consent
• Willing and able to participate in the assigned psychological intervention and complete study questionnaires at baseline, after 6 sessions, after 12 sessions, and at 3-month follow-up Exclusion Criteria

Participants will be excluded if they meet any of the following criteria:

• Pregnancy at the time of enrollment, due to the potential influence of pregnancy and childbirth during the treatment or follow-up period on psychological outcomes
• Currently receiving psychotherapy of any type that began less than 3 months prior to enrollment
• Initiation of psychiatric medication less than 3 months prior to enrollment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Brief SEE FAR CBT Intervention; Participants in this arm will receive 6 focused sessions of Brief SEE FAR CBT, a newly developed protocol emphasizing intrusive PTSD symptoms. After completing the 6 focused sessions, participants will continue to complete the full 12-session SEE FAR CBT protocol.	Behavioral: Brief SEE FAR CBT Intervention; Brief SEE FAR CBT is a focused trauma-oriented cognitive-behavioral intervention based on the SEE FAR CBT approach. The brief protocol consists of 6 sessions delivered approximately once weekly, with emphasis on intrusive PTSD symptoms. Participants will then continue treatment to complete the full 12-session SEE FAR CBT protocol.
Experimental: Dynamic Psychotherapy Treatment as Usual; Participants in this arm will receive dynamic psychotherapy as treatment as usual, delivered approximately once weekly.	Behavioral: Dynamic Psychotherapy Treatment as Usual; Participants will receive dynamic psychotherapy as treatment as usual, delivered approximately once weekly. This comparison condition represents the standard psychological treatment provided to participants in this clinical setting.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in PTSD symptoms	PTSD Checklist for DSM-5 (PCL-5) PTSD symptoms will be assessed using the PCL-5. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. Change in PCL-5 total score will be examined from baseline to after 6 sessions, from baseline to after 12 sessions, from baseline to 3-month follow-up, from after 6 sessions to after 12 sessions, and from after 12 sessions to 3-month follow-up.	Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in anxiety symptoms	Generalized Anxiety Disorder-7 (GAD-7) Anxiety symptoms will be assessed using the GAD-7. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Change in GAD-7 total score will be examined from baseline to after 6 sessions, from baseline to after 12 sessions, from baseline to 3-month follow-up, from after 6 sessions to after 12 sessions, and from after 12 sessions to 3-month follow-up.	Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in depressive symptoms	Patient Health Questionnaire-9 (PHQ-9) Depressive symptoms will be assessed using the PHQ-9. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Change in PHQ-9 total score will be examined across the four study assessment points.	Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in perceived stress	Perceived Stress Scale (PSS) Perceived stress will be assessed using the PSS. Total scores range from 0 to 40, with higher scores indicating greater perceived stress. Change in PSS total score will be examined across the four study assessment points.	Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in resilience	Connor-Davidson Resilience Scale (CD-RISC) esilience will be assessed using the CD-RISC. Total scores range from 0 to 40, with higher scores indicating greater resilience. Change in CD-RISC total score will be examined across the four study assessment points.	Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in somatic symptoms	Patient Health Questionnaire-15 (PHQ-15) Somatic symptoms will be assessed using the PHQ-15. Total scores range from 0 to 30, with higher scores indicating greater somatic symptom severity. Change in PHQ-15 total score will be examined across the four study assessment points.	Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in trauma-related use of imagination and coping	FRAME Trauma-related use of imagination and coping will be assessed using the FRAME questionnaire. The FRAME is a 21-item measure of fantastic reality ability, defined as the capacity to use imagination in response to stress or trauma. Items are rated on a 1-7 Likert scale, and mean scores range from 1 to 7, with higher scores indicating greater fantastic reality ability. Change in FRAME score will be examined across the four study assessment points.	Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in sleep quality	Brief Version of the Pittsburgh Sleep Quality Index Sleep quality will be assessed using the brief version of the Pittsburgh Sleep Quality Index. Change in sleep quality score will be examined across the four study assessment points.	Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention
Change in PTSD-related functional impairment	PTSD-related functional impairment will be assessed using the functional impairment section of the Posttraumatic Diagnostic Scale (PDS). This section includes 7 items assessing the extent to which PTSD-related problems interfered with work, relationships, leisure activities, family relationships, sex life, general life satisfaction, and overall functioning during the past two weeks. Items are rated from 0 to 4, and total scores range from 0 to 28, with higher scores indicating greater functional impairment. Change in functional impairment score will be examined across the four study assessment points.	Baseline, 6 weeks after baseline, 12 weeks after baseline, and 3 months after completion of the intervention

Collaborators and Investigators

• Sponsor: Community Stress Prevention Center
• Collaborators: Tel Hai College; The Center for Psychological Services Sha'ar Hanegev
• Investigators: Principal Investigator: Meital Mashash, PhD, Community Stress Prevention Center; Principal Investigator: Sivan Raz, PhD, Tel Hai College

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): March 1, 2028

Study Registration Dates

• First Submitted: July 1, 2026
• First Submitted That Met QC Criteria: July 13, 2026
• First Posted (Actual): July 17, 2026

Study Record Updates

• Last Update Posted (Actual): July 17, 2026
• Last Update Submitted That Met QC Criteria: July 13, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: PTSD; Intervention; Brief SEE FAR CBT
• Additional Relevant MeSH Terms: Trauma and Stressor Related Disorders; Mental Disorders; Stress Disorders, Traumatic; Stress Disorders, Post-Traumatic
• Other Study ID Numbers: BRIEF-SEE-FAR-CBT-PTSD-2026

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Individual participant data will not be shared due to the sensitive clinical nature of the data and participant privacy considerations.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No